Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 16901
Country/Region: Ethiopia
Year: 2018
Main Partner: Southern Nations, Nationalities, and Peoples' Region - Ethiopia
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: HHS/CDC
Total Funding: $3,208,800 Additional Pipeline Funding: $200,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $266,046
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $306,433
Care: Pediatric Care and Support (PDCS) $135,922
Laboratory Infrastructure (HLAB) $354,832
Strategic Information (HVSI) $50,000
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $515,245
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,273,904
Treatment: Pediatric Treatment (PDTX) $306,418
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 2
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 23
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 22
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 36
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 12
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 43
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 113
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 37
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 83
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 142
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 11
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 78
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 9
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 9
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 9
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 295
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 262
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 402
GEND_GBV Number of people receiving post-GBV care 2019 664
HTS_SELF 2019 324
HTS_SELF 15-19, Female, Directly-Assisted 2019 32
HTS_SELF 15-19, Male, Directly-Assisted 2019 26
HTS_SELF 20-24, Female, Directly-Assisted 2019 48
HTS_SELF 20-24, Male, Directly-Assisted 2019 43
HTS_SELF 25-29, Female, Directly-Assisted 2019 48
HTS_SELF 25-29, Male, Directly-Assisted 2019 55
HTS_SELF 30-34, Female, Directly-Assisted 2019 41
HTS_SELF 30-34, Male, Directly-Assisted 2019 34
HTS_SELF 35-39, Female, Directly-Assisted 2019 41
HTS_SELF 35-39, Male, Directly-Assisted 2019 35
HTS_SELF 40-49, Female, Directly-Assisted 2019 29
HTS_SELF 40-49, Male, Directly-Assisted 2019 43
HTS_SELF 50+, Female, Directly-Assisted 2019 10
HTS_SELF 50+, Male, Directly-Assisted 2019 10
HTS_SELF Directly-Assisted 2019 324
HTS_SELF FSW, Directly-Assisted 2019 497
HTS_TST <5, Unknown Sex, Negative 2019 297
HTS_TST 15-19, Female, Negative 2019 70
HTS_TST 15-19, Male, Negative 2019 45
HTS_TST 20-24, Female, Negative 2019 248
HTS_TST 20-24, Male, Negative 2019 151
HTS_TST 25-29, Female, Negative 2019 5,716
HTS_TST 25-29, Female, Negative 2019 847
HTS_TST 25-29, Female, Negative 2019 345
HTS_TST 25-29, Female, Negative 2019 334
HTS_TST 25-29, Male, Negative 2019 3,046
HTS_TST 25-29, Male, Negative 2019 969
HTS_TST 25-29, Male, Negative 2019 289
HTS_TST 25-29, Male, Negative 2019 334
HTS_TST 30-34, Female, Negative 2019 382
HTS_TST 30-34, Female, Negative 2019 694
HTS_TST 30-34, Female, Negative 2019 258
HTS_TST 30-34, Female, Negative 2019 333
HTS_TST 30-34, Male, Negative 2019 1,523
HTS_TST 30-34, Male, Negative 2019 593
HTS_TST 30-34, Male, Negative 2019 316
HTS_TST 30-34, Male, Negative 2019 327
HTS_TST 35-39, Female, Negative 2019 2,284
HTS_TST 35-39, Female, Negative 2019 694
HTS_TST 35-39, Female, Negative 2019 258
HTS_TST 35-39, Female, Negative 2019 165
HTS_TST 35-39, Male, Negative 2019 1,907
HTS_TST 35-39, Male, Negative 2019 593
HTS_TST 35-39, Male, Negative 2019 316
HTS_TST 35-39, Male, Negative 2019 165
HTS_TST 40-49, Female, Negative 2019 1,523
HTS_TST 40-49, Female, Negative 2019 497
HTS_TST 40-49, Female, Negative 2019 306
HTS_TST 40-49, Female, Negative 2019 165
HTS_TST 40-49, Male, Negative 2019 1,907
HTS_TST 40-49, Male, Negative 2019 736
HTS_TST 40-49, Male, Negative 2019 379
HTS_TST 40-49, Male, Negative 2019 165
HTS_TST 50+, Female, Negative 2019 60
HTS_TST 50+, Male, Negative 2019 60
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 48,576
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 1,157
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 1,169
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 1,236
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 382
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 382
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 1,144
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 761
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 1,523
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 1,523
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 542
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 443
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 804
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 743
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 169
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 169
HTS_TST Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative 2019 369
HTS_TST Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative 2019 487
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 69
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 97
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 97
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 165
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 135
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 334
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 299
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 69
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 69
HTS_TST_POS <5, Unknown Sex, Positive 2019 6
HTS_TST_POS 20-24, Female, Positive 2019 6
HTS_TST_POS 20-24, Male, Positive 2019 2
HTS_TST_POS 25-29, Female, Positive 2019 352
HTS_TST_POS 25-29, Female, Positive 2019 11
HTS_TST_POS 25-29, Female, Positive 2019 7
HTS_TST_POS 25-29, Female, Positive 2019 19
HTS_TST_POS 25-29, Male, Positive 2019 189
HTS_TST_POS 25-29, Male, Positive 2019 11
HTS_TST_POS 25-29, Male, Positive 2019 6
HTS_TST_POS 25-29, Male, Positive 2019 19
HTS_TST_POS 30-34, Female, Positive 2019 22
HTS_TST_POS 30-34, Female, Positive 2019 8
HTS_TST_POS 30-34, Female, Positive 2019 6
HTS_TST_POS 30-34, Female, Positive 2019 19
HTS_TST_POS 30-34, Male, Positive 2019 93
HTS_TST_POS 30-34, Male, Positive 2019 8
HTS_TST_POS 30-34, Male, Positive 2019 7
HTS_TST_POS 30-34, Male, Positive 2019 19
HTS_TST_POS 35-39, Female, Positive 2019 140
HTS_TST_POS 35-39, Female, Positive 2019 8
HTS_TST_POS 35-39, Female, Positive 2019 6
HTS_TST_POS 35-39, Female, Positive 2019 7
HTS_TST_POS 35-39, Male, Positive 2019 117
HTS_TST_POS 35-39, Male, Positive 2019 8
HTS_TST_POS 35-39, Male, Positive 2019 7
HTS_TST_POS 35-39, Male, Positive 2019 7
HTS_TST_POS 40-49, Female, Positive 2019 95
HTS_TST_POS 40-49, Female, Positive 2019 4
HTS_TST_POS 40-49, Female, Positive 2019 6
HTS_TST_POS 40-49, Female, Positive 2019 7
HTS_TST_POS 40-49, Male, Positive 2019 117
HTS_TST_POS 40-49, Male, Positive 2019 8
HTS_TST_POS 40-49, Male, Positive 2019 7
HTS_TST_POS 40-49, Male, Positive 2019 7
HTS_TST_POS 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 32
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 67
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 46
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 95
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 95
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 18
PMTCT_ART Already on ART at beginning of current pregnancy 2019 452
PMTCT_ART New on ART 2019 213
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 665
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 737
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 183
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 920
PMTCT_EID Sum of Infant Age disaggregates 2019 920
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 4
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 136
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 3
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 134
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 277
TB_PREV By Age/Sex (Numerator): <15, Female 2019 642
TB_PREV By Age/Sex (Numerator): <15, Male 2019 643
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 5,775
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 5,779
TB_PREV IPT, Life-long ART, Already, Positive 2019 10,663
TB_PREV IPT, Life-long ART, New, Positive 2019 2,176
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 12,839
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 13,179
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 659
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 657
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 5,934
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 5,929
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 10,939
TB_PREV_den IPT, Life-long ART, New, Positive 2019 2,240
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 156
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,522
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 156
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,944
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 3,778
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 3,813
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 156
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,516
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 156
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,985
TX_CURR 25-29, Female, Positive 2019 1,212
TX_CURR 25-29, Male, Positive 2019 519
TX_CURR 30-34, Female, Positive 2019 3,512
TX_CURR 30-34, Male, Positive 2019 1,074
TX_CURR 35-39, Female, Positive 2019 3,221
TX_CURR 35-39, Male, Positive 2019 1,231
TX_CURR 40-49, Female, Positive 2019 7,477
TX_CURR 40-49, Male, Positive 2019 5,378
TX_CURR Age/Sex: <1 2019 102
TX_CURR Age/Sex: <1-9 2019 1,992
TX_CURR Age/Sex: 10-14 Female 2019 615
TX_CURR Age/Sex: 10-14 Male 2019 699
TX_CURR Age/Sex: 15-19 Female 2019 1,313
TX_CURR Age/Sex: 15-19 Male 2019 1,067
TX_CURR Age/Sex: 20-24 Female 2019 1,613
TX_CURR Age/Sex: 20-24 Male 2019 1,128
TX_CURR Age/Sex: 50+ Female 2019 5,029
TX_CURR Age/Sex: 50+ Male 2019 3,024
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 40,234
TX_CURR Sum of age/sex disaggregates 2019 2,380
TX_NEW 25-29, Female, Positive 2019 116
TX_NEW 25-29, Male, Positive 2019 95
TX_NEW 30-34, Female, Positive 2019 334
TX_NEW 30-34, Male, Positive 2019 269
TX_NEW 35-39, Female, Positive 2019 318
TX_NEW 35-39, Male, Positive 2019 281
TX_NEW 40-49, Female, Positive 2019 718
TX_NEW 40-49, Male, Positive 2019 681
TX_NEW By Age/Sex: <1 2019 14
TX_NEW By Age/Sex: 1-9 2019 54
TX_NEW By Age/Sex: 10-14 Female 2019 124
TX_NEW By Age/Sex: 10-14 Male 2019 117
TX_NEW By Age/Sex: 15-19 Female 2019 65
TX_NEW By Age/Sex: 15-19 Male 2019 30
TX_NEW By Age/Sex: 20-24 Female 2019 28
TX_NEW By Age/Sex: 20-24 Male 2019 118
TX_NEW By Age/Sex: 50+ Female 2019 289
TX_NEW By Age/Sex: 50+ Male 2019 214
TX_NEW FSW 2019 33
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 3,865
TX_NEW Pregnancy status 2019 356
TX_NEW Sum of Age/Sex disaggregates 2019 985
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 35,840
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 752
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 178
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 784
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 177
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 17,305
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 3,043
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 11,535
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 2,043
TX_PVLS_den Denominator: Indication: Routine 2019 30,397
TX_PVLS_den Denominator: Indication: Targeted 2019 5,441
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 171
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 175
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 3,501
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,839
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 5,686
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 5,775
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 157
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 160
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,449
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,009
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 39,695
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2019 462
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2019 10
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2019 10
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2019 210
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2019 232
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 1,087
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 1,084
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 18,761
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 18,763
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 1,431
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 14
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 356
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 1,801
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 33,956
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 3,571
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 1,805
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 363
Cross Cutting Budget Categories and Known Amounts Total: $1,610,800
Gender: Gender Based Violence (GBV) $92,500
Post GBV Care
Implementation
Capacity building
Key Populations: MSM and TG $100,000
Training of health workers and community outreach workers
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Renovation $150,000
Condoms: Policy, Tools, and Services $50,000
Adolescent Girls and Young Women (AGYW) $80,000
Human Resources for Health $1,110,000
Water $28,300